Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUNS: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366Phase 2Recruiting
- Sponsor
- University of British Columbia
- Start
- Sep 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of apalutamide, Abiraterone Acetate Tablets (I), docetaxel, niraparib, atezolizumab in prostate cancer (PCa), sponsored by University of British Columbia. Started Sep 2021; status: recruiting.
02
Drugs
apalutamideAbiraterone Acetate Tablets (I)docetaxelniraparibatezolizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04812366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812366.